Methylated derivatives of yohimbane, process of preparation and process of medicinalutilization



United States Patent O 3,218,325 METHYLATED DERIVATIVES OF YOHIMBANE, PROCESS OF PREPARATION AND PROCESS OF MEDICINAL UTILIZATION Georges Muller, Nogent sur Marne, Andr Allais, Paris, and Roland Bardoneschi, Tremblay les Gonesses, France, assignors to Roussel-UCLAF, S.A., Paris, France, a corporation of France No Drawing. Filed Oct. 14, 1964, Ser. No. 403,941 Claims priority, application France, Mar. 21, 1961, 856,302; June 21, 1961, 865,615 1 Claim. (Cl. 260287) This application is a continuation-in-part of our cpending United States patent application Serial No. 180,- 862, filed March 19, 1962, now abandoned.

The present invention relates to a new derivative of yohimbane, levorotatory in pyridine, 6,6-dimethyl-16/3- carbomethoxy 17cc methoxy 18,8-(3',4,5'-trimethoxybenzoyloxy)-3B,20a-yohimbane of the formula in the form of the free base or pharmacologically acceptable mineral or organic, simple or double acid addition salts, intermediates useful in preparing the same, the process for production of these compounds and the method of utilizing these compounds as a sedative and hypotensive free of adverse side effects.

Reserpine and its analogs such as deserpidine are of known physiological benefit as hypotensors, sedatives and tranquilizers. They have the drawback, however, of causing adverse side effects particularly on long administration and are contra-indicated for patients with peptic ulcers. It has long been an aim of workers in the field to develop a reserpine analog which was as efficacious as reserpine without the well known adverse side effects.

The side effects to reserpine as well as their frequency are reported in the article of A. W. Krogsgaard entitled Side Effects of Reserpine in the Treatment of Essential 'Hypertension (Acta Medica Scandinavica, CLXII, page Side effects: Developed in, percent Nasal symptoms 41 Dyspnoea Phlebitis 4 Oedemas 4 Diarrhoea 5 Fatigue 35 Dreams 8 Weight gain 35 Mental depression l7 In addition, cases of digestive hemorrhages and gastro duodenal ulcers have been reported by:

M. Levrat and R. Lamvert (Archives des Maladies de lappareil digestif et des Maladies de la nutrition, 48, 426 (1959)).

W. 0. West (5 cases in 42 patients) (Annals of Internal Medicine, 48, 1958).

These authors point out that reserpine exerts an ulcerigenic influence in man which must be feared when the medicament is administered in doses in excess of 2 mg./ day.

Deserpidine has similar side effects although the toxicity is somewhat attenuated. According to Mercks Index, 7th edition, 1960, page 203, the dosage range is from 0.1 to 5 mg./day. In the original paper on deserpidine by Schneider et al., J. Pharm. Expt. Therap. 114, 10 (1955) entitled Pharmacological Studies with Deserpidine, A New Alkaloid from Rauwolfia Canescens, the authors state:

The pharmacological effects of deserpidine were compared to those of reserpine. No significant differences between the effects of the two alkaloids could be found. This indicates that the methoxy group in ring A of reserpine is not essential for its pharmacological activity.

An object of the present invention is to obtain yohimbane compounds selected from the group consisting of levorotatory in pyridine 6,6-dimethyl-l6B-carbomethoxy- 17a methoxy 185 (3',4',5-trimethoxybenzoyloxy)-3p, 20a-yohimbane of the formula OCH;

OCH;

OCH3

and its pharmacologically acceptable acid addition salts.

Another object of the invention is to develop a process for the production of levorotatory in pyridine 6,6-dimethyl carbomethoxy-l7a-methoxy-18(3-(3',4',5'-trimethoxybenzoyloxy) -3 l3,20u-yohimbane.

A further object of the invention is to obtain intermediates useful in producing levorotatory in pyridine 6,6-dimethyl 16fi-carbomethoxy-l7a-methoxy-18B-( 3',4',5'-trimethoxybenzoyloxy)3;8,20a-yohimbane such as:

3 6,6-dimethyl-1GB-carbomethoxy-17a-methoxy-18B-ace toxy-3 a,20a-yohimbane, 6,6-dimethyl-16/8-carbomethoxy-17a-methoxy-18B-hydroxy-3fi,20or-yohimbane, 6, 6-dimethyl-1 6/3-c arb omethoxy- 17 oc-methoxy- 1 SB-hydroxy-3 a,20a-yohimb ane.

It is a still further object of this invention to provide a method of treating hypertension with a decrease in tendency toward ulcers through the continued dosage of a levorotatory in pyridine 6,6-dimethy1-16fi-carbomethoxy- 17oz methoxy 18p (3',4',5' trimethoxybenzoyloxy)- 3p,20a-yohimbane.

It is another object of this invention to provide a method of tranquilization and sedation with a decrease in tendency toward ulcers through continued dosage of a levorotatory in pyridine 6,6-dirnethyl-16fl-carbornethoxy- 17a methoxy 18B (3',4',5' trimethoxybenzoyloxy)- 3p,20u-yohimbane.

These and other objects of the invention will become more apparent as the description thereof proceeds.

We have found, and this represents our invention, that levorotatory in pyridine 6,6-dimethy1-16B-carbomethoxy- 17a methoxy 18/3 (3,4',5 trimethoxybenzoyloxy)- 3fl,20u-yohimbane has a physiological activity similar to reserpine without the commitment adverse side effects. A description of the pharmacodynamical properties will be set forth subsequently.

The process of preparation of the compound and its salts is illustrated by Table I.

TABLE I II O CH III O OH;

OCH:

This process is characterized essentially by the condensation of dextrorotatory in pyridine 1 fi-carboxymethy1-2fl-carbomethoxy-3a methoxy-4fi-acetoxy-6fl-formylcyclohexane, III, or one of its esters, with 6,;3-dimethyltryptamine, II. The transformation of the Schiff base so obtained into product of Formula I is made by application of known methods.

According toa preferred method of execution of the 2fl-carbomethoxy-3a-methoxy-4B acetoxy-6 3-formy1 cy- The condensation product, the 6,6-dimethyl-l6fl-carbomethoxy-lh-methoxy 18 3 acetoxy 2,3-3,4-disec0- A -20a-yohimbene-3-oic acid, IV, is converted into levorotatory in pyridine 6,6-dimethyl-16B-carbomethoxyl7a-methoxy-18B (3',4,5' trimethoxybenzoyloxy)-3fi, 20a-yohirnbane, I, by the course of reactions indicated hereafter.

The 6,6-dimethyl16/3-carbomethoxy-l7a-methoXy-18,8- acetoxy-2,3-3,4 diseco-A -20a-yohimbene-3-0ic acid, IV, is reduced by the action of an alkali metal borohydride, such as potassium borohydride, into 6,6-dimethyl- 16fl-carbomethoxy-17a methoxy l8B-acetoxy 2,3-3,4- diseco-20a-yohimbane-3-oic acid, V. This latter compound is cyclized by heating into 6,6-dimethyl-16p3-carbomethoxy-lh-methoxy 185 acetoxy 2,3-seco-3-oxo- 20a-yohimbane, VI. Compound VI is further cycl-ized by action of phosphorus oxychloride into dextrorotatory in pyridine 6,6-dimethyl-16B carbomethoxy-17a-methoxy- 18,8-acetoxy-A -20a-yohimbene, VII. This latter compound is reduced by means of zinc in the presence of perchloric acid. The levoratatory in pyridine 6,6-dimethyl- 16/3-carbomethoxy-17a-methoxy l8fl-acetoxy-3fi,20a-yohimbane, VIII, is separated from its isomer, the 6,6-dimethyl-l6/3-carbomethoxy 17a-methoxy-18fi-acetoxy-3a, 20a-yohimbane, VIIIa. This latter compound, VIIIa, may be converted into the desired 3/8-isomer by the action of formic acid at elevated temperatures. Next the Elli-isomer (compound VIII) is selectively saponified by the action of potassium borohydride into 6,6-dimethyl- 165-carbomethoXy-17a methoxy-l8fi-hydroxy-3B,20a-yohimbane, IX. This compound is esterified by action of 3,4,5-trimethoxybenzoyl chloride and finally the desired levorotatory in pyridine 6,6-dimethyl-l6fl-carbomethoxyl7a-methoxy l8fl-(3,4',5' trimethoxybenzoyloxy)-3fi, 20u-yohimbane, I, is obtained.

Following the usual operatory methods, the pharmacologically-acceptable acid addition salts of levorotatory in pyridine 6,6-dimethyl-l6,6-carbomethoxy-l7amethoxy-l8fi-(3',4',5 trimethoxybenzoyloxy) 3 3,200:- yohimbane, such as salts of mineral acids of the nature of hydrohalic acids, sulfuric acid, nitric acid, perchloric acid, phosphoric acid; organic acids of the nature of lower alkanoic acids, lower alkanedioic acids, aryl-sulfonic acids, aromatic carboxylic acids and even monoor polyhydroxylated acids may be'formed in the presence or in the absence of a diluent, either directly or by double decomposition.

The following examples serve to illustrate the present invention without, however, limiting the same thereto. More particularly, the conditions and/or the order of the reaction steps may be varied, the nature of the solvents, acids, or bases used may be modified, and other changes and variations may be made by those skilled in the art in accordance with the principles set forth herein and in the claims annexed hereto. Final esterification can also be carried out by following the procedure described by Robert Joly et al., US. Patent No. 2,926,167.

EXAMPLE I .Preparation of levorotatory in pyridine 6,6-dimethyl-16B carbometh0xy-l7a-meth0xy-18B-(3', 4',5'-trimethoxy-benz0yl0xy) -3,B,20a-y0himbane, I

Step A: Preparation of 6,6-dimethyl-1ofi-carbomethoxy- 17a-meth0xy-18fl acetoxy 2,3-3,4 'diseco A -20ayohimbene-3-0ic acid, I V.-2 g. of dextrorotatory in pyridine l,B-carboxy-methyl-ZB-carbomethoxy 3a-methoxy 4/3-acetoxy-6,6-formylcyclohexane, III, were introduced into 4 cc. of water and 1 cc. of dimethylformamide. The solution was cooled to 10 C. and slowly, under agitation, 1.1 cc. of triethylamine was added. The solution was allowed to stand under agitation at 10 C. for a' period of about 12 minutes. Then the solution of 1 g. of 3,,8-dimethyl-tryptamine, II, in 1 cc. of dimethylformamide and 0.5 cc. of water was added. The reaction mixture was maintained under agitation at 10 C. for a period of about 15 minutes. The resultant solution 6 of 6,6-dimethyl-l6/3-carbomethoxy-17a-methoxy-18,8-acetoXy-2,3-3,4-diseco-A -20a-yohimbene-3-oic acid, IV, was used as such for the following steps of thesynthesis.

This compound is not described in the literature.

3,}8-Dimethyl-tryptamine, II, was prepared following the process described in the French Patent No. 1,296,586.

Compound III is obtained according to the process described in US. Patent No. 2,952,682.

Step B: Preparation of 6,6-dimethyl-l6/8-carb0methoxy- I7a-meth0xy-18B-acetoxy 2,3 -3,4-disec0-20-y0himbane- 3-0ic acid, V.-Following the method of operation described in US. Patent No. 2,988,552, Example 3, the solution of compound IV, obtained according to Step A, was reduced and a solution of 6,6-dime thyl-16/3-car bomethoxy-17a-methoxy-1SB-acetoxy 2,3-3,4-diseco-20ayohimbane-3-oic acid, V, was obtained which was utilized for the following step.

This compound is not described in the literature.

Step C Preparation of 6,6-dimethyl-16B-carb0methoxy- 1 7 oc-melhOJQ'J 8fl-acetoxy-2,3 seco-j-ox0-20a-y0himbane, VI.FolloWing the method of operation described in US. Patent No. 2,988,552, Example 4, the solution of compound V, obtained in the preceding step, was subjected to heating and raw 6,6 dimethyl 16B carbomethoxy-17a-methoXy-18B acetoxy-2,3-seco-3-oxo-20a-yohimbane, VI, was obtained which was used as such for the next step.

This compound is not described in the literature.

Step D: Preparation of dextrorotatory in pyridine 6,6- dimethyl-lofi-carbomethoxy-l7a-methoxy acetoxy- A -20ay0himbene, VII.-Following the method of operation described in US. Patent No. 2,907,769, Example 11, the C ring of compound VI, obtained according .to Step C, is cyclized and 4.2 g. of dextrorotatory in pyridine, 6,6-dimethyl-l6fi-carbomethoxy 17a methoxy-18/3-acetoxy-A -20a-yohimbene, VII, having a melting point of about -195 C. and a specific rotation [a] =+120 :5" (c.=0.5% in pyridine), were obtained.

The compound was soluble in acetone and chloroform, slightly soluble in alcohol, very slightly soluble in ether.

Analysis.C H O N molecular Calculated: C, 69.00%; H, 7.13%; N, 6.19%. C, 68.9%; H, 7.1%; N, 6.3%.

This compound is not described in the literature.

Step E: Preparation of levorotatary in pyridine 6,6-dimethyl-16,8-carbometh0xy-17a methoxy 18B acetmcy- 3,8,2 0a-yohimbane, VIM-Following the method of operation described in US. Patent No. 2,907,769, Example 12(b), 6.5 g. of compound VII, obtained according to the preceding step, were reduced and 950 mg. of levorot-atory in pyridine, 6,6-dimethyl-16B-carbomethoxy-17amethoxy-18B-acetoxy-3B, 20a-yohimbane. VIII, were obtained having a melting point of 261 C. and a specific rotation [a] =89 i5" (C.=0.5% in pyridine).

The product was soluble in chloroform, slightly soluble in alcohol and acetone.

This compound is not described in the literature.

In the course of the execution of the process, there was also formed the Soc-isomer of compound VIII, that is to say, 6,6-dimethyl-16,8-carbomethoxy-17a methoxy- 18fi-acetoxy-3a,20a-yohimbane, VIIIa, which was separated from its isomer by chromatography over alumina. The 3a-isomer has a melting point of about C.

It was soluble in alcohol, ether, acetone and chloroweight=452.53 Found:

' form.

This compound is not described in the literature.

In addition, there was also isolated from the reaction mixture, 6,6-dimethyl-16fi-carbomethoxy 17a methoxy- 18fl-hyd roXy-3a,20a-yohimbane, IXa, having a melting point of 284 C.

This product was soluble in acetone and chloroform, slightly soluble in alcohol, insoluble in ether.

s or rectal methods. 7

Analysis.C H O N molecular weight=4l2.5l.

Calculated: C, 69.88%; H, 7.82%. Found: C, 69.75%;

thoxy-17a-meth0xy 186 hydroxy 3,8,20 yohimbane,

IX .-Following the method of operation described in US. Patent No. 2,907,769, Example 13, 0.5 g. of compound .VIII, obtained according to the preceding step, were selectively saponified and 400 mg. of raw 6,6-di-met hyll6p-carbomethoxy-l7a methoxy-185 hydroxy 3,8,20ocyohimbane, 1X, were obtained which were used as such for the next step of the synthesis.

This compound is not described in the literature.

Step G: Preparation of levorotazory in pyridine 6,6-dimethyl-16,8-carbmethoxy-l 7a methoxy 18B (3,4',5'-

trimethoxy-benzoyloxy)-3fl,20a yohimbane, I.-- Follow- .ing the method of operation described in US. Patent No. 2,907,769, Example 14, 0.4 g. of compound IX, obtained .according to Step F, were e-sterified and 0.2 g. of levoro- 'tatory in pyridine 6,6-dimethyl-16B --carbomethoxy- 17amethoxy-l8,8 (3',4,5,-trimethoxy-benzoyloxy) 3fl,20ucyohimbane, I, were obtained having a melting .point of.

200 and 245 C., and a specific rotation [a] =-164 :10 (c.=0.25% in pyridine).

This product was soluble in acetone and chloroform, slightly soluble in alcohol and ether.

Analysis.C H O N molecular weight=606.69.

Calculated: c, 67.31%; H, 6.98%; N, 4.62%. Found:

C, 67.2%; H, 7.2%; N, 4.9%.

This compound is not described in the literature. The product, compound I, possesses interesting pharmacological properties. It possesses particularly a neurosedative action. nervoussystem is equal in intensity to that of reserpine This depressive action on the central and its analogs, but without the troublesome secondary effects of diarrhea, profound adynamia, and stomach ulcers provoked by these compounds. Compound I possesses also an anti-hypertensive action at least equal to that of reserpine. It can be used for the treatment of disturbances of comportment due to anxiety psychosis, to hyperemotivity, to spasms, and to hyperexcitation. 'Because of its anti-hypertensive action, it is best utilized in order to eliminate nervous troubles in hypertensive people. In addition it"can be used in geriatrics for patients in the states of permanent irritability, in the states of excitability due to a premenstrual or menopausic syndrome,

and in the phenomena of insomnia by reenforcing the ambulatory treatment without secondary inconveniences.

Levorotatory in pyridine 6,6-dimethyl 16p carbomethoxy-lh-methoxy-18 8-(3,4,5 trimethoxybenzoyloxy)-3/3,20a-yohimbane is utilized by oral, transcutaneous It can be prepared in the form of injectable solutions or injecta'ble suspensions, prepared im ampules, in multiple dose flacons, in the form of tablets and in the form of suppositories.

. animal as a function of the method of administration.

The pharmaceutical forms such as injectable solutes or suspensions, tablets and suppositories are prepared according to the usual process.

Example II.(1 Pharmacological study of levorotatory in pyridine 6,6 dimethyl-I 6p-carb0meth0xy-1 7u-methoxy 18p (3,4',5'-trimeth0xybenzoyloxy) 3520ayohimbane (6,6-dz'methyl deserpidine) (a) DETERMINATION OF THE NEURO-DEPRES SOR EFFECT Test of ptosis of the eyelids in rats.The research on the neuro-depressive effect was made on the rat by means of the test of the ptosis of the eyelids such as described and codified by Rubin et al., J. Pharm. Exp. Therap. 1957, 120, 125.

The product was injected intraperitoneally in lots of 5 rats and readings were made each hour for a period of 6 hours after the injections, and then on the next day.

The table below gives the observed results:

TABLE II Degree of Ptosis Doses 'y/kg.

' 5 hours after 6 hours after 24 hours after injection injection injection according to the graphic method of Tainter and Miller. The 50% efiective dose, ED is equal to 205 'y/ kg. i507.

Comparatively, the ED of reserpine and deserpidine are as follows:

Reserpine about 200 'y/kg. Deserpidine about 250 'y/kg.

The product exercises thus according to this test a neurodepressive power equal to that of reserpine. It is to be remarked, however, that the eiiect of reserpine at low dosages exhausts itself generally in 24 hours in the doses utilized or at least the effect is considerably diminished. By contrast, the action of 6,6-dimethyl-16,8-carbomethoxya methoxy 18,6 (3,4',5' trimethoxybenzoyloxy)- 313,20u-yohimbane has only been moderately weakened. However at high dosages, the efiect of reserpine persists for a longer period of time than that of 6,6-dimethyl-l6ficarbomethoxy-l7a-methoxy 18,8 (3,4',5' trimetho-xybenzoyloxy)-3fl,20oc-yohimbane.

Test of the turning cylinder.In this test the neuro-depressive effect is estimated by the number of falls of mice placed in lots of 5 on a horizontal cylinder in rotation about its axis. Normal mice hold their equilibrium by displacing themselves in an inverse sense to that of the movement of the cylinder. The speed of rotation is chosen such that the number of falls per animal does not -10 and 20 mg./kg. doses of 6,6-dimethyl-16fl-carbome- .thoxy-17ot-methoxy 18p (3',4',5 trimethoxybenzoyl- ,oxy)-3.p,20a-yohimbane by intraperitoneal injection.

9 TABLE III.--TURNING CYLINDER TEST D represents 6,6-dimethy1-16B-carbomethoxy-lM-methoxy-IS-fi(3, 4, 5-trirnethoxybenzoyloxy)-3B,20a-yohimbane.

R represents reserpine.

As is shown in Table III, the said compound exercises a total effect similar to that of reserpine. However, two important differences are observed:

(1) The maximum neuro-depressor effect of 6,6-dimethyl 165 carbomethoxy 17a methoxy 18B (3,- 4,5-trimethoxybenzoyloxy)-3p,20a-yohimbane is obtained 24 hours after the injections, whereas the effect of reserpine attains its maximum in about 4 hours.

(2) The effect of the reserpine as measured according to this test which utilizes much larger doses than those utilized in the test of ptosis of the eyelids, is exhausted after 24 hours in a dose of 1 mg./kg., the effect of which is very weak. In larger doses of reserpine the return to normal is effected progressively and very slowly. Very important residual effects are noted three and four days after the administration of 2, 5, and 20 mg./ kg. This residual effect is all the more marked when the dosage is more elevated. Under the same conditions, 6,6-dimethyl 16B carbomethoxy 17a methoxy 18/3 (3',- 4,5-trirnethoxybenzoyloxy)-3,8,20a-yohimbane does not provoke the residual effect. On the contrary, the return to normal is more rapid than with reserpine and the effects observed the third and fourth day are nil or negligible.

These results show that the neuro-depressor power of 6,6-dimethyl-16,8-carbomethoxy 17oz methoxy-l8j9-(3, 4',5'-trimethoxybenzoyloxy)-3l3,20a-yohimbane is almost equal to that of reserpine the day of the treatment, a little superior the next day and again almost equal the second day. It is, in contrast to reserpine, very inferior the third and fourth days.

In the results observed, where the residual effects of reserpine continue three or four days after injection of elevated doses, the important factor to consider is the safety of the dosage rather than the pharmacodynamic effect. Here one should understand the important advantage had by 6,6-dimethyl-16,8-carbomethoxy-17amethoxy 18B (3',4',5-trimethoxybenzoyloxy) 3 8,200- yohimbane from the point of view of safety.

(b) DETERMINATION OF THE ANTI-HYPER'IENSIVE EFFECT The injection by intraperitoneal methods of 6,6-dimethyl-l65-carbomethoxy 17cc methoxy 18 8 (3',4',5-trimethoxybenzoyloxy)-3[3,20a-yohimbane in a dose of 100 7/ kg. to rats rendered artificially hypertensive by administration of desoxycorticosterone acetate and ingestion of salt water (see Green, Ann. Internal. Med. 1953, 39, 333, and Peterfalvi et al. Arch. Intern. Pharmacodynamie, 1960, 124, 237) brings a noticeable lowering of the arterial pressure.

As is shown in Table IV, the injection of 6,6-dimethyl- 16 fi-carbomethoxy-17a-methoxy-18B-(3',4',5-trimethoxybenzoyloxy-3fl,20a-yohimbane causes the restoration of the arterial pressure, which in hypertensive rats had attained a value of about 19 cm. of mercury, to the neighborhood of its normal value, which is about 12 cc. of mercury.

TABLE IV Arterial Pressure Lowering Dose Lowering in percent At the in percent Average Initial maximum per dose of effect 18 12.6 30 200 'y/kg 17 11 35 34 comparatively, 100 'y/ kg. of reserpine cause an average lowering in percent of 23.2% and 200 7/ kg. of reserpine cause an average lowering in percent of 32.7%. Similarly, deserpidine causes an average decrease in percent of 22% at 100 'y/kg. and 32% at 200 'y/kg. Under the conditions of this test, an average lowering of the artificially induced hypertension of 3234% to the normal pressure is the maximum attainable.

The anti-hypertensive effect of 6,6-dimethyl-I6/3-carbomethoxy 17a methoxy-18/3-(3,4',5-trimethoxybenzoyloxy)-3fl,20u-yohimbane is similar to that observed for reserpine and deserpidine under the same conditions.

(2) Determination of the toxicity (a) ACUTE TOXICITY The test of acutetoxicity was effected on mice of the Rockland strain weighing from 20 to 22 g. 6,6-dimethyl- 16,8 carbomethoxy-17a-methoxy-18/3-(3,4,5-trimethox ybenzoyloxy)-3 8,20a-yohimbane, dissolved in an aqueous solvent, was injected to lots of ten mice by intraperitoneal methods, in doses of 1, 2, 5, 10 and 20 mg./kg., respectively. The animals were held under observation for a period of five days. A neurodepressive symptomatology typical of reserpine was observed. No mortality was noted during the period of observation in any of the doses injected. The 50% lethal dose, DL is thus greater than 20 mg./kg.

(b) CHRONIC TOXICITY Lots of five male rats received daily, except Sunday, doses of 507 to l mg./kg. of 6,6-dimethyl-16fi-carbomethoxy-lh-methoxy-18fl-(3',4',5 trimethoxybenzoyloxy)- 3fi,20a-yohimbane by subcutaneous methods. Each rat had thus received a total of nine injections during a period of 10 days. The animals were weighed every other day. Their consumption of food was determined each day. The state of sedation was evaluated every day by a reading of the ptosis of the eyelids made before the injection of that day. At the end of the test the animals were autopsied. The ulcers of the stomach were determined and noted;

F and the thymus, testicles, the seminal vesicules and the prostate were weighed.

Similar tests were parallelly made with reserpine. One identical lot of untreated animals served as a control lot.

The 50% effective dose, as concerning the neurosedative effect (evaluated by the degree of ptosis of the eyelids) in this semi-chronic test, was found identical for the compound studied and for reserpine. It was 500 7/ kg.

At the end of the treatment, there was noted for the stronger dose of 1 mg./ kg. of 6,6-dimethyl-16fi-carbomethoxy-17a-methoxy (3,4,5'-trimethoxybenzoyloxy)-3fl,20a-yohimbane:

(1) A slight slackening of growth with reference to the controls, but a gain in weight with reference to the initial weight (whereas with reserpine, the weight dropped about 35% (2) A very slight drop of consumption of food, as compared with the controls, whereas this decreased considerably for the lot treated with reserpine.

(3) A zero mortality, whereas the lot treated with reserpine had a mortality of 40% (4) An absence of stomach ulcers, whereas the lot treated with reserpine showed stomach ulcers in all of the rats.

(5) A slight lowering of weight of the thymus in a ratio with the slackening of growth rate, whereas with the lot treated with reserpine there was an actual disintegration of thymus.

(6) No modification of the weight of the testicles,

whereas the weight of the testicles of rats treated with oxy) -3B,20a-yohimbane per day was well tolerated. The

50% lethal dose of this compound by standard acute toxicity tests on mice is greater than 20 mg./kg. The maximum tolerated daily dose Without undesirable effects a was 50 to 100 7/ kg. for reserpine.

This test of chronic toxicity demonstrates that 6,6-ditrimethoxybenzoyoxy)3fl,20a-yohinrbane has a neurodepressor efiect analogous to that of reserpine and an almost total absence of secondary toxic eifects.

The above examples are illustrative of the invention without, however, limiting the same, and enable those skilled in the art to understand the invention. It is obvious that other expedients may be employed without departing from the spirit of the invention or the scope of the appended claim.

We claim:

A yohimbane compound selected from the group consisting of levorotatory in pyridine 6,6-dimethyl-l6 3-carbooXy)- 3B,20u-yohimbane of the formula and its pharmacologically-acceptable acid addition salts.

References Cited by the Examiner UNITED STATES PATENTS 2,786,843 3/1957 Huebner 260287 2,788,309 4/1957 Cooper l6767 3,031,453 4/1962 Lucas 260-287 3,048,592 8/1962 Muller et a1. 260--287 WALTER A. MODANCE, Primary Examiner. 

